{"product_id":"cst-65837s","title":"CST,  65837S, Phospho-LRRK2 (Ser1292) (E8M3A) Rabbit Monoclonal Antibody","description":"Monoclonal Antibody for studying LRRK2 (Ser1292) phosphate. Validated for Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-LRRK2 (Ser1292) (E8M3A) Rabbit Monoclonal Antibody (CST #65837) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nImmunoprecipitation: 1:50\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Immunoprecipitation\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nPhospho-LRRK2 (Ser1292) (E8M3A) Rabbit Monoclonal Antibody recognizes transfected levels of LRRK2 protein only when phosphorylated at Ser1292.\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nMonoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser1292 of human LRRK2 protein.\n\u003cb\u003eBackground\u003c\/b\u003e\nParkinson's disease (PD), the second most common neurodegenerative disease after Alzheimer's, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Research studies have shown various genes and loci are genetically linked to PD including α-synuclein\/PARK1 and 4, parkin\/PARK2, UCH-L1\/PARK5, PINK1\/PARK6, DJ-1\/PARK7, LRRK2\/PARK8, synphilin-1, and NR4A2 (2). Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival (4). Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5). Autophosphorylation of Ser1292 is a suggested marker of LRRK2 kinase activity and phosphorylation at this site is enhanced by several familial PD mutations, including the G2019S mutation (6).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\naugmented in rheumatoid arthritis 17; AURA17; Dardarin; leucine rich repeat kinase 2; leucine-rich repeat kinase 2; Leucine-rich repeat serine\/threonine-protein kinase 2; LRRK2; PARK8; RIPK7; ROCO2\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Transfected Only\nMW (kDa): 290\nSource\/Isotype: Rabbit IgG","brand":"CST","offers":[{"title":"Default Title","offer_id":46800248340649,"sku":"65837S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-65837s","provider":"Iright","version":"1.0","type":"link"}